



SDI Review Form 1.6

Journal Name:	International Journal of Research and Reports in Hematology
Manuscript Number:	Ms_IJR2H_47045
Title of the Manuscript:	EVALUATION OF EFFECT OF IMATINIB ON BONE MARROW FIBROSIS IN CHRONIC MYELOID LEUKEMIA PATIENTS
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The idea of the research is very important for the field of cancer and very interesting, but the way in which the aim was written has not been well explained this. The methods part is the most sought after parts of the idea and how it works and access. As for the part of the results and discussion, the cytology and the molecular, although the researcher has said that they did their work but where their results in the research, which effect on the idea of the research.	<ul style="list-style-type: none"> The aim was re-written (highlighted) The results of the cytology and molecular are represented in table (1) and table (4) as regarding the response (hematological, cytogenetic and molecular response).
Minor REVISION comments		
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	The study was approved by the Ethical Committee of Faculty of Medicine, Assiut University (IRB no: IRB00008718). Informed consents were taken from the patients before enrollment in this study.